© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 8, 519-529,
April 17, 1996
© 1996 Oxford University Press
p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center Houston
Department of Biomathematics, The University of Texas M. D. Anderson Cancer Center Houston
Department of Pathology, The University of Texas M. D. Anderson Cancer Center Houston
Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center Houston
Department of Clinical Investigation, The University of Texas M. D. Anderson Cancer Center Houston
Correspondence to: Dong M. Shin, M.D., Department of Thoracic/Head and Neck Medical Oncology, Box 080, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.
BACKGROUND:: The survival rate for head and neck squamous cell carcinoma remains poor despite therapeutic advances over the last two decades. For patients with disease confined to the head and neck, there are two major and biologically distinct patterns of treatment failures after definitive therapy: recurrence of primary disease and development of second primary tumors. Understanding the biological basis of patterns of treatment failure after definitive therapy is needed to guide the development of adjuvant treatment and strategies to prevent second primary tumors.
PURPOSE:: To determine whether expression of the p53 protein has prognostic significance and/or is associated with patterns of treatment failure, we examined protein expression in primary tumor specimens of patients with head and neck squamous cell carcinoma.
METHODS:: Immunohistochemical analysis with a monoclonal antibody (D07) specific for p53 protein was used to detect expression of the protein in formalin-fixed, paraffin-embedded tumor samples from 69 head and neck cancer patients treated with definitive local therapy (surgery and/or radiotherapy) between January 1980 and October 1983 at The University of Texas M. D. Anderson Cancer Center. We quantitated p53 protein expression and assessed its association with duration of patient survival, patterns of treatment failure (recurrence of primary tumor and development of second primary tumor), and other clinical parameters. All reported P values resulted from two-sided statistical tests.
RESULTS:: We found detectable levels of p53 protein expression in the tumor cell nuclei of 41 of 69 patients. Thirty-six (52%) of 69 patients whose tumors exhibited p53 protein expression in greater than or equal to 10% of the cell nuclei were grouped as p53 positive, and 33 (48%) of 69 patients whose tumors exhibited less than 10% nuclear expression were grouped as p53 negative. The clinical characteristics of the patients in the p53-positive and p53-negative groups were well balanced. Overall survival was significantly lower, and the times to tumor recurrence, to second primary tumors, and to any treatment failure were significantly shorter in the p53-positive group than in the p53-negative group (P =. 0002, P = .047, P = .003, and P= .0009, respectively), mainly because the p53 positivity was associated with earlier development of tumor recurrence and second primary tumors. The rate of second primary tumor development per person per year was also significantly higher in the p53-positive group than in the p53-negative group. By use of multivariate analysis according to the Cox regression model, p53 expression status was identified as the most significant predictor of overall survival duration (P = .007), time to tumor recurrence (P = .053), time to second primary tumors (P = .035), and time to any treatment failure (P = .004).
CONCLUSIONS:: The expression of p53 protein in primary head and neck squamous cell carcinoma was significantly predictive of shorter survival because of its association with earlier development of both tumor recurrence and second primary tumors. Thus, p53 expression may be a valuable marker for identifying individuals at high risk of developing a recurrence of primary disease and second primary tumors who may benefit from adjuvant therapy and chemoprevention after definitive local therapy. [J Natl Cancer Inst 1996; 88: 519–29]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A.R.M. R. Amin, F. R. Khuri, Z. Chen, and D. M. Shin Synergistic Growth Inhibition of Squamous Cell Carcinoma of the Head and Neck by Erlotinib and Epigallocatechin-3-Gallate: The Role of p53-Dependent Inhibition of Nuclear Factor-{kappa}B Cancer Prevention Research, June 1, 2009; 2(6): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Smith, D. Wang, L. M. Rubenstein, W. A. Morris, L. P. Turek, and T. H. Haugen Association between p53 and Human Papillomavirus in Head and Neck Cancer Survival Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 421 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Choi and J.N. Myers Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy Journal of Dental Research, January 1, 2008; 87(1): 14 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward Clin. Cancer Res., June 15, 2006; 12(12): 3661 - 3697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Celetti, D. Testa, S. Staibano, F. Merolla, V. Guarino, M. D. Castellone, R. Iovine, G. Mansueto, P. Somma, G. De Rosa, et al. Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness Clin. Cancer Res., November 15, 2005; 11(22): 8019 - 8027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Bergamo, L. C. da Silva Veiga, P. P. dos Reis, I. N. Nishimoto, J. Magrin, L. P. Kowalski, J. A. Squire, and S. R. Rogatto Classic and Molecular Cytogenetic Analyses Reveal Chromosomal Gains and Losses Correlated with Survival in Head and Neck Cancer Patients Clin. Cancer Res., January 15, 2005; 11(2): 621 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sirianni, P. K. Ha, M. Oelke, J. Califano, W. Gooding, W. Westra, T. L. Whiteside, W. M. Koch, J. P. Schneck, A. DeLeo, et al. Effect of Human Papillomavirus-16 Infection on CD8+ T-Cell Recognition of a Wild-Type Sequence p53264-272 Peptide in Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., October 15, 2004; 10(20): 6929 - 6937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Rhee, F. R. Khuri, and D. M. Shin Advances in Chemoprevention of Head and Neck Cancer Oncologist, June 1, 2004; 9(3): 302 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Casson, S. C. Evans, A. Gillis, G. A. Porter, P. Veugelers, S. J. Darnton, D. L. Guernsey, and P. Hainaut Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1121 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Akervall, U. Bockmuhl, I. Petersen, K. Yang, T. E. Carey, and D. M. Kurnit The Gene Ratios c-MYC:Cyclin-dependent Kinase (CDK)N2A and CCND1:CDKN2A Correlate with Poor Prognosis in Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., May 1, 2003; 9(5): 1750 - 1755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Geisler, A. F. Olshan, M. C. Weissler, J. Cai, W. K. Funkhouser, J. Smith, and K. Vick p16 and p53 Protein Expression as Prognostic Indicators of Survival and Disease Recurrence from Head and Neck Cancer Clin. Cancer Res., November 1, 2002; 8(11): 3445 - 3453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. McGregor, A. Muntoni, J. Fleming, J. Brown, D. H. Felix, D. G. MacDonald, E. K. Parkinson, and P. R. Harrison Molecular Changes Associated with Oral Dysplasia Progression and Acquisition of Immortality: Potential for Its Reversal by 5-Azacytidine Cancer Res., August 15, 2002; 62(16): 4757 - 4766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Hoffmann, A. D. Donnenberg, S. D. Finkelstein, V. S. Donnenberg, U. Friebe-Hoffmann, E. N. Myers, E. Appella, A. B. DeLeo, and T. L. Whiteside Frequencies of Tetramer+ T Cells Specific for the Wild-Type Sequence p53264-272 Peptide in the Circulation of Patients with Head and Neck Cancer Cancer Res., June 1, 2002; 62(12): 3521 - 3529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. de Melo, K. d. C. B. Ribeiro, L. P. Kowalski, and D. Deheinzelin Risk Factors for Postoperative Complications in Oral Cancer and Their Prognostic Implications Arch Otolaryngol Head Neck Surg, July 1, 2001; 127(7): 828 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Homann, M. Nees, C. Conradt, A. Dietz, H. Weidauer, H. Maier, and F. X. Bosch Overexpression of p53 in Tumor-distant Epithelia of Head and Neck Cancer Patients Is Associated with an Increased Incidence of Second Primary Carcinoma Clin. Cancer Res., February 1, 2001; 7(2): 290 - 296. [Abstract] [Full Text]
|
|
|
|
|
|
C.-A. O. Nathan, K. Sanders, F. W. Abreo, R. Nassar, and J. Glass Correlation of p53 and the Proto-Oncogene eIF4E in Larynx Cancers: Prognostic Implications Cancer Res., July 1, 2000; 60(13): 3599 - 3604. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. D. Smith, G. L. Smith, D. Carter, C. T. Sasaki, and B. G. Haffty Prognostic Significance of Vascular Endothelial Growth Factor Protein Levels in Oral and Oropharyngeal Squamous Cell Carcinoma J. Clin. Oncol., May 10, 2000; 18(10): 2046 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Shin, L. Mao, V. M. Papadimitrakopoulou, G. Clayman, A. El-Naggar, H. J. C. Shin, J. J. Lee, J. S. Lee, A. Gillenwater, J. Myers, et al. Biochemopreventive Therapy for Patients With Premalignant Lesions of the Head and Neck and p53 Gene Expression J Natl Cancer Inst, January 5, 2000; 92(1): 69 - 73. [Full Text] [PDF]
|
|
|
|
|
|
A. Homma, Y. Furuta, N. Oridate, Y. Nakano, G. Kohashi, K. Yagi, T. Nagahashi, S. Fukuda, K. Inoue, and Y. Inuyama Prognostic Significance of Clinical Parameters and Biological Markers in Patients with Squamous Cell Carcinoma of the Head and Neck Treated with Concurrent Chemoradiotherapy Clin. Cancer Res., April 1, 1999; 5(4): 801 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. H. Dunphy, F. R. Dunphy, J. H. Boyd, M. A. Varvares, H. J. Kim, V. Lowe, T. L. Dunleavy, J. Rodriguez, E. M. McDonough, and J. Minster Expression of p53 Protein in Advanced Head and Neck Squamous Cell Carcinoma Before and After Chemotherapy Arch Otolaryngol Head Neck Surg, November 1, 1997; 123(11): 1223 - 1225. [Abstract] [PDF]
|
|
|
|
 |
|
 G R Ogden Recurrence of malignant tumours in the head and neck BMJ, September 21, 1996; 313(7059): 700 - 701. [Full Text]
|
|